Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Kura Oncology (NASDAQ: KURA).The analyst commented, "Beyond the menin launch ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE